Tacrolimus
- Generic Name
- Tacrolimus
- Brand Names
- Advagraf, Astagraf, Envarsus, Modigraf, Prograf, Protopic, Tacforius
- Drug Type
- Small Molecule
- Chemical Formula
- C44H69NO12
- CAS Number
- 104987-11-3
- Unique Ingredient Identifier
- Y5L2157C4J
- Background
Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condi...
- Indication
Immediate-release formulations of tacrolimus are indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic liver, kidney, heart, or lung transplants, in combination with other immunosuppressants. Extended-release formulations of tacrolimus are indicated for the prophylaxis of organ rejection in adult and pediatric ...
- Associated Conditions
- Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Lung Transplant Rejection, Oral Lichen Planus, Psoriasis, Pyoderma Gangrenosum, Rheumatoid Arthritis, Severe Atopic Dermatitis, Vitiligo, Moderate Atopic dermatitis
- Associated Therapies
- -
Comparative FK506 Drug Levels of Once Daily Advagraf in First Nations and Caucasian Patients With Liver Transplants
- First Posted Date
- 2020-01-23
- Last Posted Date
- 2020-01-23
- Lead Sponsor
- University of Manitoba
- Target Recruit Count
- 20
- Registration Number
- NCT04237246
- Locations
- 🇨🇦
John Buhler Research Centre Health Sciences Centre, Winnipeg, Manitoba, Canada
Reduced Intensity BMT for Immune Dysregulatory and Bone Marrow Failure Syndromes Using Post-Transplant Cyclophosphamide
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2024-12-06
- Target Recruit Count
- 27
- Registration Number
- NCT04232085
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-01-07
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT04220008
Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma
- First Posted Date
- 2019-12-19
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Srinivas Devarakonda
- Target Recruit Count
- 1
- Registration Number
- NCT04205240
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2019-11-26
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 36
- Registration Number
- NCT04177004
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Autologous Transplant Targeted Against Crohn's
- Conditions
- Interventions
- First Posted Date
- 2019-11-06
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT04154735
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation
- First Posted Date
- 2019-10-16
- Last Posted Date
- 2020-10-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT04127721
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)
- First Posted Date
- 2019-09-19
- Last Posted Date
- 2023-02-08
- Target Recruit Count
- 11
- Registration Number
- NCT04095858
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania ( Site 0309), Philadelphia, Pennsylvania, United States
🇺🇸City of Hope ( Site 0302), Duarte, California, United States
🇺🇸The University of Chicago Medical Center ( Site 0306), Chicago, Illinois, United States
Everolimus Monotherapy as Immunosuppression After Liver Transplant
- First Posted Date
- 2019-08-21
- Last Posted Date
- 2023-05-23
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 14
- Registration Number
- NCT04063865
- Locations
- 🇺🇸
IU Health University Hospital, Indianapolis, Indiana, United States
Study of Tacrolimus vs Mycophenolate Mofetil in Pediatric Patients With Nephrotic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2019-08-07
- Last Posted Date
- 2023-10-17
- Target Recruit Count
- 270
- Registration Number
- NCT04048161
- Locations
- 🇨🇳
Children's Hospital of Chongqing Medical University, Chongqing, Chongqing, China
🇨🇳Peking University First Hospital, Beijing, Beijing, China
🇨🇳First Affiliated Hospital of Zhongshan Medical University, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.